Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, overp
Target Price
The average target price of NUVB is 11 and suggests 92% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell